Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    diode laser, onychomycosis
Previous Study | Return to List | Next Study

Diode Laser Treatment of Onychomycosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01452490
Recruitment Status : Completed
First Posted : October 14, 2011
Last Update Posted : October 28, 2020
Sponsor:
Information provided by (Responsible Party):
Cynosure, Inc. ( ConBio, a Cynosure Company )

Brief Summary:
The purpose of this study is to evaluate the V-Raser diode laser system with investigational Nail Fungus Handpiece in the treatment of onychomycosis.

Condition or disease Intervention/treatment Phase
Onychomycosis Device: Diode Laser Treatment Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Even though this study has recruited more than 10 participants, it is a feasibility study, designed to test the prototype rather than measuring health outcomes. It is to confirm the operating specifications before beginning a full clinical trial.
Masking: None (Open Label)
Primary Purpose: Device Feasibility
Official Title: Study of the V-Raser Diode Laser System in the Treatment of Onychomycosis
Study Start Date : October 2011
Actual Primary Completion Date : August 2013
Actual Study Completion Date : August 2013

Arm Intervention/treatment
Experimental: Diode Laser Treatment Device: Diode Laser Treatment
Laser treatment once every 6 weeks, for a total of 4 treatment sessions
Other Name: V-Raser




Primary Outcome Measures :
  1. Amount of Clear Nail Growth from Baseline in mm or as measurement of total area of involvement [ Time Frame: 12 months ]
    Amount of lesion-free toenail growth (mm or total area of involvement) from Baseline, as judged by computer software analysis of photos.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed subungual onychomycosis in a great toe that does not extend to the eponychium
  • Fitzpatrick Skin Type I-IV
  • Written and verbal informed consent
  • Able to comply with study instructions and to return to the clinic for required visits
  • Agrees to refrain from other active topical, laser or light-based treatment to the great toes
  • Agrees to the use of Naftin Gel between the toes to prevent/control tinea pedis

Exclusion Criteria:

  • Pregnancy, breastfeeding or planning to become pregnant
  • History of cutaneous photosensitivity, porphyria and hypersensitivity to porphyrins or photodermatoses
  • Any skin pathology or condition that could interfere with the evaluation or that requires the use of interfering topical or systemic therapy
  • Coagulation disorder or current use of anti-coagulation medication (including aspirin use of greater than 81 mg per day)
  • Any condition which, in the investigator's opinion, would make it unsafe for the subject to participate
  • Enrolled in an investigational drug or device trial, or has been treated with an investigational device or received an investigational drug within 30 days
  • Oral Lamisil within 1 year, Sporanox or over-the-counter topicals within 1 month, or other prescription anti-fungal medications or topicals within 6 months
  • Evidence of diabetic neuropathy or peripheral vascular disease related to diabetes, or a loss of protective sensation in the affected foot
  • Psoriasis, lichen planus, infection involving the lunula, prior surgical treatment of the affected great toe within 1 year, or a history of trauma to the affected great toe
  • Immunocompromised status, or with existing (or history of) cancer/skin malignancy
  • Distal nail thickness of greater than 2mm in the affected great toenail

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01452490


Locations
Layout table for location information
United States, Connecticut
Shoreline Foot and Ankle Center
New London, Connecticut, United States, 06320
Shoreline Foot and Ankle Center
Westbrook, Connecticut, United States, 06498
Sponsors and Collaborators
ConBio, a Cynosure Company
Investigators
Layout table for investigator information
Principal Investigator: Darren Courtright, DPM Shoreline Foot and Ankle Center
Layout table for additonal information
Responsible Party: ConBio, a Cynosure Company
ClinicalTrials.gov Identifier: NCT01452490    
Other Study ID Numbers: D4-11-F
First Posted: October 14, 2011    Key Record Dates
Last Update Posted: October 28, 2020
Last Verified: October 2020
Keywords provided by Cynosure, Inc. ( ConBio, a Cynosure Company ):
Onychomycosis
Toenail Fungus
Additional relevant MeSH terms:
Layout table for MeSH terms
Onychomycosis
Tinea
Dermatomycoses
Skin Diseases, Infectious
Infection
Mycoses
Nail Diseases
Skin Diseases